Abstract
To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c. Secondary endpoints included change from baseline in body weight, blood pressure, heart rate and incidence of hypoglycaemia, gastrointestinal adverse effects, pancreatitis and diabetic retinopathy. A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included. We identified only 1 trial with oral semaglutide. Compared with placebo, subcutaneous semaglutide 0.5 and 1 mg reduced HbA1c by 1.01% (95% CI, 0.56-1.47) and 1.38% (1.05-1.70), respectively. Both doses demonstrated superior glycaemic efficacy compared to other antidiabetic agents, including sitagliptin, exenatide, liraglutide, dulaglutide and insulin glargine. Semaglutide also had a beneficial effect on body weight (mean difference vs placebo -4.11 kg, 95% CI -4.85 to -3.37 for semaglutide 1 mg) and systolic blood pressure. We did not observe increased hypoglycaemia rates wi...Continue Reading
References
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Aug 8, 2007·Annals of Internal Medicine·George A DiamondSanjay Kaul
Jul 22, 2009·PLoS Medicine·Alessandro LiberatiDavid Moher
Mar 30, 2010·Neuromuscular Disorders : NMD·F Muntoni, UNKNOWN Meeting Steering Committee and TREAT-NMD Network
Aug 26, 2010·Cardiovascular Research·Kathleen J GriffioenMark P Mattson
Jan 29, 2013·BMJ Open·Louise E RobinsonJoseph P O'Hare
Dec 17, 2014·Diabetes Care·Troels M JensenWilliam M Steinberg
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
May 11, 2016·Systematic Reviews·Lars JørgensenAsbjørn Hróbjartsson
May 18, 2016·The Journal of Urology·David F Penson
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Dec 17, 2016·Diabetes, Obesity & Metabolism·Zin Z HtikeMelanie J Davies
Jan 24, 2017·The Lancet. Diabetes & Endocrinology·Christopher SorliStephen C Bain
Mar 28, 2017·The Lancet. Diabetes & Endocrinology·Vanita R ArodaJ Hans DeVries
Apr 8, 2017·The Lancet. Diabetes & Endocrinology·Bo AhrénFrancis Chow
May 21, 2017·Diabetologia·Christoph KapitzaAnne Flint
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 9, 2017·Diabetes, Obesity & Metabolism·Yutaka SeinoShizuka Kaneko
Oct 20, 2017·JAMA : the Journal of the American Medical Association·Melanie DaviesJulio Rosenstock
Nov 28, 2017·Diabetes, Obesity & Metabolism·Tina VilsbøllMichael Larsen
Dec 17, 2017·Diabetes Care·Andrew J AhmannVanita R Aroda
Jan 13, 2018·Diabetes, Obesity & Metabolism·Kohei KakuArihiro Kiyosue
Feb 6, 2018·The Lancet. Diabetes & Endocrinology·Richard E PratleyUNKNOWN SUSTAIN 7 investigators
Feb 17, 2018·BMJ Open Diabetes Research & Care·Gian Paolo FadiniAngelo Avogaro
Apr 21, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Michal WitkowskiHrvoje Vrazic
Apr 25, 2018·Diabetes, Obesity & Metabolism·Mark WarrenBertrand Cariou
Citations
Oct 7, 2018·Diabetes Care·Melanie J DaviesJohn B Buse
Aug 24, 2018·Diabetes, Obesity & Metabolism·Gian Paolo FadiniUNKNOWN DARWIN-T2D Network
Feb 16, 2019·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Georgios A ChristouDimitrios N Kiortsis
Sep 26, 2019·Heart·Gaurav S GulsinGerry P McCann
Oct 23, 2019·Diabetes, Obesity & Metabolism·Ioannis AvgerinosEleni Bekiari
May 20, 2020·Expert Opinion on Drug Safety·Rajesh Peter, Steve C Bain
Oct 28, 2019·Chronic Illness·Anastasia-Stefania AlexopoulosMatthew J Crowley
Jun 2, 2020·Expert Review of Clinical Pharmacology·Richard A Chudleigh, Stephen C Bain
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Jennifer D Goldman
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Susan Cornell
Aug 14, 2018·Endocrine·Xuejing LiGuoqiang Liu
Oct 6, 2018·Diabetologia·Melanie J DaviesJohn B Buse
Jul 31, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraManilka Sumanatilleke
Nov 7, 2019·Current Diabetes Reports·Patricia R Peter, Beatrice C Lupsa
Jun 15, 2020·Current HIV/AIDS Reports·Aaren KettelhutNicholas T Funderburg
Sep 24, 2020·Diabetes, Obesity & Metabolism·Ying ShuaiWenying Yang
Dec 16, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Zhen RuanHao Hu
Dec 17, 2020·PloS One·Daniel Christopher RainkieNada Nabil Abdelkader
Jun 2, 2020·Advanced Drug Delivery Reviews·D J BraydenR J Mrsny
Nov 11, 2020·Journal of Diabetes and Its Complications·Gustavo Monteiro EscottSandra Pinho Silveiro
Mar 9, 2021·Endocrinology and Metabolism·Hun Jee Choe, Young Min Cho
Mar 13, 2021·Diabetes, Obesity & Metabolism·Kirsten DahlTine A Baekdal
Mar 26, 2021·British Journal of Pharmacology·Johanna HelmstädterSebastian Steven
Jul 1, 2019·Metabolism: Clinical and Experimental·Anastasia-Stefania Alexopoulos, John B Buse
Jul 17, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraNitin Kapoor
Sep 8, 2021·Journal of Comparative Effectiveness Research·Margaret F ZupaKenneth J Smith
Dec 12, 2021·Clinical Drug Investigation·Feiyu WangPinfang Huang
Dec 7, 2021·Diabetes, Obesity & Metabolism·Ke HeZeng Jing
Jul 7, 2021·Reviews in Endocrine & Metabolic Disorders·Ehab BakbakDavid A Hess